LRMR
Price
$3.45
Change
+$0.06 (+1.77%)
Updated
Nov 19, 04:59 PM (EDT)
Capitalization
295.71M
118 days until earnings call
Intraday BUY SELL Signals
MDNAF
Price
$1.05
Change
+$0.02 (+1.94%)
Updated
Nov 18 closing price
Capitalization
85.86M
84 days until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

LRMR vs MDNAF

Header iconLRMR vs MDNAF Comparison
Open Charts LRMR vs MDNAFBanner chart's image
Larimar Therapeutics
Price$3.45
Change+$0.06 (+1.77%)
Volume$18.79K
Capitalization295.71M
Medicenna Therapeutics
Price$1.05
Change+$0.02 (+1.94%)
Volume$32.52K
Capitalization85.86M
LRMR vs MDNAF Comparison Chart in %
LRMR
Daily Signal:
Gain/Loss:
MDNAF
Daily Signal:
Gain/Loss:
View a ticker or compare two or three
VS
LRMR vs. MDNAF commentary
Nov 20, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is LRMR is a Hold and MDNAF is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Nov 20, 2025
Stock price -- (LRMR: $3.45 vs. MDNAF: $1.05)
Brand notoriety: LRMR and MDNAF are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: LRMR: 87% vs. MDNAF: 41%
Market capitalization -- LRMR: $295.71M vs. MDNAF: $85.86M
LRMR [@Biotechnology] is valued at $295.71M. MDNAF’s [@Biotechnology] market capitalization is $85.86M. The market cap for tickers in the [@Biotechnology] industry ranges from $106.82B to $0. The average market capitalization across the [@Biotechnology] industry is $2.15B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

LRMR’s FA Score shows that 1 FA rating(s) are green whileMDNAF’s FA Score has 0 green FA rating(s).

  • LRMR’s FA Score: 1 green, 4 red.
  • MDNAF’s FA Score: 0 green, 5 red.
According to our system of comparison, MDNAF is a better buy in the long-term than LRMR.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

LRMR’s TA Score shows that 4 TA indicator(s) are bullish while MDNAF’s TA Score has 5 bullish TA indicator(s).

  • LRMR’s TA Score: 4 bullish, 5 bearish.
  • MDNAF’s TA Score: 5 bullish, 6 bearish.
According to our system of comparison, both LRMR and MDNAF are a bad buy in the short-term.

Price Growth

LRMR (@Biotechnology) experienced а +2.52% price change this week, while MDNAF (@Biotechnology) price change was +2.35% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -2.17%. For the same industry, the average monthly price growth was -5.68%, and the average quarterly price growth was +64.91%.

Reported Earning Dates

LRMR is expected to report earnings on Mar 18, 2026.

MDNAF is expected to report earnings on Feb 12, 2026.

Industries' Descriptions

@Biotechnology (-2.17% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
LRMR($296M) has a higher market cap than MDNAF($85.9M). MDNAF YTD gains are higher at: -10.044 vs. LRMR (-10.724). MDNAF has higher annual earnings (EBITDA): -21.81M vs. LRMR (-108.21M). LRMR has more cash in the bank: 139M vs. MDNAF (20.5M). MDNAF has less debt than LRMR: MDNAF (162K) vs LRMR (4.61M). LRMR (0) and MDNAF (0) have equivalent revenues.
LRMRMDNAFLRMR / MDNAF
Capitalization296M85.9M345%
EBITDA-108.21M-21.81M496%
Gain YTD-10.724-10.044107%
P/E RatioN/AN/A-
Revenue00-
Total Cash139M20.5M678%
Total Debt4.61M162K2,848%
FUNDAMENTALS RATINGS
LRMR vs MDNAF: Fundamental Ratings
LRMR
MDNAF
OUTLOOK RATING
1..100
6672
VALUATION
overvalued / fair valued / undervalued
1..100
19
Undervalued
47
Fair valued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
10097
PRICE GROWTH RATING
1..100
5537
P/E GROWTH RATING
1..100
100100
SEASONALITY SCORE
1..100
5050

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

LRMR's Valuation (19) in the null industry is in the same range as MDNAF (47). This means that LRMR’s stock grew similarly to MDNAF’s over the last 12 months.

LRMR's Profit vs Risk Rating (100) in the null industry is in the same range as MDNAF (100). This means that LRMR’s stock grew similarly to MDNAF’s over the last 12 months.

MDNAF's SMR Rating (97) in the null industry is in the same range as LRMR (100). This means that MDNAF’s stock grew similarly to LRMR’s over the last 12 months.

MDNAF's Price Growth Rating (37) in the null industry is in the same range as LRMR (55). This means that MDNAF’s stock grew similarly to LRMR’s over the last 12 months.

MDNAF's P/E Growth Rating (100) in the null industry is in the same range as LRMR (100). This means that MDNAF’s stock grew similarly to LRMR’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
LRMRMDNAF
RSI
ODDS (%)
Bullish Trend 2 days ago
79%
Bearish Trend 2 days ago
87%
Stochastic
ODDS (%)
Bullish Trend 2 days ago
86%
Bullish Trend 2 days ago
87%
Momentum
ODDS (%)
Bearish Trend 2 days ago
86%
Bearish Trend 2 days ago
89%
MACD
ODDS (%)
N/A
Bearish Trend 2 days ago
88%
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
87%
Bullish Trend 2 days ago
81%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
89%
Bullish Trend 2 days ago
78%
Advances
ODDS (%)
Bullish Trend 3 days ago
85%
Bullish Trend 2 days ago
82%
Declines
ODDS (%)
Bearish Trend 7 days ago
87%
Bearish Trend 7 days ago
90%
BollingerBands
ODDS (%)
Bullish Trend 2 days ago
87%
Bearish Trend 2 days ago
83%
Aroon
ODDS (%)
Bearish Trend 2 days ago
87%
Bearish Trend 2 days ago
88%
View a ticker or compare two or three
Interact to see
Advertisement
LRMR
Daily Signal:
Gain/Loss:
MDNAF
Daily Signal:
Gain/Loss:
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
DSFGY14.89N/A
N/A
Dah Sing Financial Holdings Ltd.
NNFSF6.48N/A
N/A
NONGFU SPRING CO LTD.
SFGIF10.51N/A
N/A
SHIZUOKA FINL GROUP INC.
GEODF2.64-0.07
-2.58%
Geodrill Ltd.
NUMIF0.03-0.01
-25.17%
Numinus Wellness Inc.

LRMR and

Correlation & Price change

A.I.dvisor indicates that over the last year, LRMR has been loosely correlated with OCUL. These tickers have moved in lockstep 43% of the time. This A.I.-generated data suggests there is some statistical probability that if LRMR jumps, then OCUL could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To LRMR
1D Price
Change %
LRMR100%
+1.92%
OCUL - LRMR
43%
Loosely correlated
+2.81%
MLTX - LRMR
43%
Loosely correlated
+1.12%
ERAS - LRMR
42%
Loosely correlated
-3.32%
EYPT - LRMR
42%
Loosely correlated
+2.29%
AMLX - LRMR
42%
Loosely correlated
+2.80%
More

MDNAF and

Correlation & Price change

A.I.dvisor tells us that MDNAF and LRMR have been poorly correlated (+25% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that MDNAF and LRMR's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To MDNAF
1D Price
Change %
MDNAF100%
-1.58%
LRMR - MDNAF
25%
Poorly correlated
+1.92%
VIR - MDNAF
25%
Poorly correlated
-1.18%
STOK - MDNAF
23%
Poorly correlated
-1.49%
CGEM - MDNAF
23%
Poorly correlated
-1.05%
PTCT - MDNAF
22%
Poorly correlated
-1.42%
More